AI

Man vs. Machine (Learning): Comparing Speed and Cost-Effectiveness of Manual vs. Deep Learning Segmentation-Aided Volume Delineation for Head and Neck Lymph Node Targets
This preliminary study shows that using an AI-based segmentation-aided approach to Head and Neck Lymph Node stations can be feasibly implemented within a standard Radiation…
Clinical User Experience with MVision AI
This is a webinar that you don’t want to miss! You’ll hear from an actual user and their clinical experience with MVision’s AI-powered software. Please…
Advancements in Breast Cancer Treatment: Highlights from the ESTRO 2023 Conference
The annual meeting of the European Society for Radiotherapy and Oncology (ESTRO) took place in Vienna from 12 to 15 May, gathering over 6000 professionals.…
Radiotherapy for Esophageal Cancer – The Challenge of a Difficult Site
More than half a million people are diagnosed each year with esophageal cancer. It is the 8th most common cancer type and places sixth regarding…
Press Release: MVision AI raises 5.4M€ to make same-day cancer treatment the new standard
HELSINKI, Finland – March 23, 2023 MVision AI raises 5.4M€ to make same-day cancer treatment the new standard MVision AI is the first cloud-based AI-powered…
Perspectives on the implementation of AI-based solutions for Radiation Oncology – Where are we?
One of the main characteristics of humans, compared to most other living creatures, is the ability of making tools. Progress has been linked to discoveries…
Deep learning to generate synthetic CT Images from MR for Radiotherapy treatment planning
The generation of synthetic images has greatly advanced in recent years due to the progress of artificial intelligence. Some of the applications have recently been…
NCCC Evaluation of MVision AI contouring software
S Warren, N Richmond MVision AI software has been under evaluation at NCCC (Newcastle upon Tyne Hospitals NHS Foundation Trust) since 28 February 2022* in…
Improving Tools to Fight Glioblastoma
 Background Glioblastoma multiforme represents approximately half of the cases of central nervous system malignant tumors. The median age at diagnosis is 64 years, and the…
MVision AI Receives FDA 510(k) Clearance for Guideline-Based Segmentation Radiotherapy Software
Helsinki, 31st of May, 2022 – MVision AI announces that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for guideline-based, AI-powered…